Introduction: New-onset diabetes after transplantation (NODAT) is an increasingly recognised metabolic complication of kidney transplantation that is associated with increased morbidity and mortality. This study aimed to determine the incidence of NODAT and identify risk factors for development of NODAT among kidney allograft recipients in a single centre.
Materials And Methods: We retrospectively reviewed all kidney allograft recipients in our centre between 1998 and 2007.
Background: Subclinical rejection (SCR) causes chronic allograft damage, which may be prevented by antirejection therapy.
Methods: A pilot study of the effect of routine treatment of SCR was performed in 88 recipients of either a kidney (n=59) or combined kidney-pancreas transplant (n=29) undergoing protocol biopsy (PBX) surveillance at 1 and 3 months, using calcineurin inhibitors, mycophenolate mofetil, and corticosteroid therapy.
Results: SCR was seen in 46.